UltraSpec Lab

UltraSpec Lab is a registered high-tech laboratory in British Columbia, Canada, dedicated to developing pharmaceutical formulations through the integration of AI intelligence and biochemical technology. In recent years, the UltraSpec team has used AI technology to deeply explore the advantages of supramolecular macrocycles as both active pharmaceutical molecules and new pharmaceutical excipients. They have designed and developed a series of supramolecular drug matrices, as well as nanopharmaceutical matrices and bionic delivery systems based on supramolecular assembly.
UltraSpec Lab UltraSpec Lab UltraSpec Lab UltraSpec Lab
Its research results have been published in many world-renowned academic journals such as Nature, Materials Today, and Biomaterials Science. Currently, the laboratory has established in-depth cooperation with Mitacs (Mathematics of Information Technology and Complex Systems), a Canadian organization, on biomedical diagnosis projects. It has achieved numerous breakthroughs in academic research, product development, and project implementation, and has achieved great success in projects such as β-nicotinamide mononucleotide (NMN) cell repair.

Core R&D Capabilities

Human Organ Metabolism Simulation System

Human Organ Metabolism Simulation System

A simulation system for the metabolism of various human organs has been developed to quickly verify nutritional models, significantly shortening the R&D cycle.

Deep Learning AI Model

Deep Learning AI Model

Independently developed a deep learning AI model based on the Transformer framework, enabling efficient transformation from R&D to commercialization.

Driven Data Workflow

Driven Data Workflow

Enables diversification, complexity, processization, and automation of data sources. New data sources can be accessed and used without obstacles.

Human Body Prediction Model

Human Body Prediction Model

Constructed a human body prediction model based on biological big data and AI technology, used to analyze health status, aging degree, and development trends.

Target-Protein Docking System

AI Independent Design

Utilizes artificial intelligence for independent design, rather than relying on existing proteins for docking like other companies.

Superior Docking Performance

Delivers better docking results and can address the current gaps in the structure of many pharmaceutical proteins.

mRNA Drug Design

Pioneering drug development method based on mRNA drug design.

Exclusive Partnership

Developed by Canada's ULTRASPEC Laboratory, with exclusive usage rights held by DMD Partners Canada (the only authorized entity). Canada's ULTRASPEC Laboratory is committed to big data analysis robotics technology and its integration with artificial intelligence in the pharmaceutical, testing, and big health industries. By leveraging its independent genetic database and proprietary AI correlation calculations, it effectively enhances product functionality and conducts comprehensive safety analysis.

ULTRASPEC Laboratory has repeatedly received research funding and policy support from Mitacs, Canada's federal government natural sciences and engineering research fund, in recognition of its achievements in the application of R&D results.